Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

805.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Discover which S&P500 stocks are making waves on Friday.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday. 
Via Chartmill
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients
Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years. 
Via Benzinga
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Teladoc Health is integrating LillyDirect into its Chronic Care Weight Management program, potentially boosting enrollments. 
Via Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
A global study shows obesity rates predicted to climb. Are weight loss drugs not doing enough or not available in enough countries? 
Via Benzinga
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years
Via Benzinga
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
3 Super Growth Stocks: 2 To Buy – 1 To Sell
PLTR, LLY and NVDA are probably three of the hottest, most popular stocks on the planet today. 
Via Talk Markets
Topics Stocks / Equities
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025,... 
Via Benzinga
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly? 
Via MarketBeat
Topics Bonds Economy Government
Exposures Debt Markets Economy Interest Rates
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Stock Market Sell-Off: The 9 Best Stocks to Buy Now in March (2025)
Via The Motley Fool
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Via Benzinga
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service includes home delivery, live support, and safeguards against compounded... 
Via Benzinga
2 Mega-Cap Stocks with Exciting Potential and 1 to Turn Down
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Biotech Rally Coming In Weeks Ahead?
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
Nvidia, Apple, and Eli Lilly: Manufacturing the Future
The great buildout for AI and GLP-1 drugs continues. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pfizer CEO Says Company May Shift Overseas Manufacturing To US Amid Looming Tariff Threats: 'Will The Trump Administration Co-Invest', Asks Analyst
In light of potential tariff threats from President Donald Trump, Pfizer Inc.'s (PFE.N) CEO Albert Bourla has suggested the possibility of shifting the company's overseas manufacturing to its U.S.... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors. 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market. 
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list? 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD. 
Via MarketBeat
Exposures Product Safety
Market Monitor February 26th
Market Whirlwind: Nvidia (NVDA) exceeds expectations, tensions over Trump tariffs, AppLovin drops and Lucid faces leadership crisis 
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target
Eli Lilly is investing over $50 billion in U.S. manufacturing, adding four new sites to boost domestic medicine production and create thousands of jobs. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.